Biomedica Sclerostin ELISA

Monday, 20 August, 2012 | Supplied by: United Bioresearch Products Pty Ltd

Biomedica Sclerostin ELISA

Canonical Wnt signalling plays an important role in the regulation of bone homeostasis by promoting the development of osteoblasts. Negative regulators of the Wnt pathway are important new therapeutic targets for the treatment of diseases with enhanced bone resorption. One of these molecules is Sclerostin, a 22.5 kD secreted glycoprotein, which acts by binding to the Wnt-coreceptor LRP5 thus preventing the binding of Wnt molecules. Sclerostin is nearly exclusively produced in osteocytes; therefore, it is considered a clinical marker which provides highest bone specificity.

The measurement of serum sclerostin levels is a novel approach in studying the regulation of bone mass and may serve as a tool in detecting bone disorders and monitoring the efficiency of various therapies. Areas of related research include osteoporosis, cancer-induced bone diseases, rheumatoid arthritis, chronic inflammation, kidney disease and therapy monitoring of anabolic treatment.

The Sclerostin ELISA from Biomedica is a highly sensitive ELISA for the measurement of human samples as small as 20 µL. The kit includes all necessary reagents, including standards and control, and has a convenient ready-to-use protocol.

Online: www.unitedbioresearch.com.au
Phone: 02 4575 0309
Related Products

Meridian Bioscience Specimen-specific, inhibitor-tolerant master mixes

Scientists can skip DNA/RNA extraction with Meridian's inhibitor-tolerant, specimen-specific...

Molecular Devices microplate readers

A microplate reader is an essential instrument for a vast range of applications, from basic...

Dojindo Cytotoxicity LDH Assay Kit-WST

Dojindo's Cytotoxicity LDH Assay Kit-WST can be applied with or without supernatant transfer...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd